"There are great people there at all levels and the clerks are very accommodating."
Chambers & Partners (Intellectual property) 2014
"8 New Square brims with barristers experienced in fighting fiendishly complex, high-value IT and telecoms disputes."
Chambers & Partners (Information Technology) 2014
'A veritable powerhouse of IP expertise'
Chambers and Partners 2011
"8 New Square is undoubtedly one of the leading sets for trade mark and copyright cases within the media and entertainment sphere, so much so that stablemates here frequently find themselves pitted against each other in major cases."
Chambers & Partners (Media & Entertainment) 2014
'A number of great IT and telecoms barristers.'
Legal 500 2010
'excellence on IT matters'
Legal 500 (Information Technology) 2010
"an impressive set with quality from the top
silk down to the most junior barristers."
Chambers & Partners (Information Technology) 2013
'Practical and helpful clerks" provide a "smooth and personable service.'
Chambers and Partners 2011
The clerks are described as "helpful," "generous" and "very good at knowing what you want."
Chambers & Partners (Intellectual Property) 2013
'An incredibly good set for IP matters'.
Legal 500 2010
"8 New Square brims with barristers experienced in fighting fiendishly complex, high-value IT and telecoms disputes."
Chambers & Partners 2014
'Top drawer IP set.'
Legal 500 2010
"Fantastic roster of talent" and recommended for being "very modern, forward-thinking and providing sound commercial advice" as well as offering instructing solicitors "a very broad skill set in the soft IP space."
Chambers & Partners 2017
Resolution Chemicals v H. Lundbeck A/S [2013] EWHC 739 (Pat)
Case Summary | Judgment | 15 May 2013
Michael Tappin QC and Mark Chacksfield succeeded on four preliminary issues before Mr Justice Arnold in the High Court in Resolution Chemicals v H. Lundbeck A/S [2013] EWHC 739 (Pat). Of particular interest are the decisions concerning estoppel/abuse of process due to res judicata by reason of privity of interest, and the defendant’s application for summary judgement on obviousness of the patent based on earlier unsuccessful challenges to the patent both in the UK and abroad.
The estoppel/abuse of process application concerned whether the Resolution was estopped from bringing a patent revocation action in regard of the defendant’s patent for escitalopram. The issue arose because the validity of the patent had already been challenged in proceedings brought by Arrow Generics Limited, Teva UK Limited and Teva PI. Resolution Chemicals had been part of the Arrow group from December 2001 to December 2009 and, now as an independent company, intends to purchase escitalopram for import from Teva Poland.
The judge considered that simply being under the same ultimate control as Arrow at the time of the earlier litigation was not a sufficient basis for concluding that Resolution was privy. He considered that Resolution had no actual interest in the previous litigation. The judge also rejected any allegation of joint tortfeasance with Teva Poland under the agreement to purchase escitalopram as none of the acts in issue established that Teva Poland procured the infringement or secured its commission.
With regard to the summary judgement application the judge held that Resolution does have a real prospect of success on the basis of potential further expert evidence from three experts who gave evidence in a successful challenge to the Patent in the Netherlands. He rejected the suggestion that the decisions of Dutch courts were outliers. Further the judge considered that it was not possible to say that the claimant had no real prospect of success on a new piece of prior art added by amendment, that had not been in issue in the earlier proceedings.